Bausch Health Companies Inc. Stock
There is an upward development for Bausch Health Companies Inc. compared to yesterday, with an increase of €0.11 (1.370%).
Currently there is a rather positive sentiment for Bausch Health Companies Inc. with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 16 € shows a very positive potential of 96.44% compared to the current price of 8.15 € for Bausch Health Companies Inc..
For the coming years our community has positive and negative things to say abot the Bausch Health Companies Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Revenue growth" there were negative voices in the community.
Pros and Cons of Bausch Health Companies Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bausch Health Companies Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Bausch Health Companies Inc. | 1.370% | -0.196% | -10.485% | 27.405% | 12.159% | -68.034% | -61.544% |
Opko Health Inc. | 1.930% | 1.068% | 27.080% | -6.518% | -17.670% | -67.054% | -45.280% |
Catalent Inc. | 0.330% | 0.384% | 0.694% | 31.970% | 26.845% | -45.563% | 52.184% |
Repligen Corp. | -1.120% | 4.746% | -9.011% | 14.614% | -7.816% | -14.993% | - |
Comments
Bausch Health Companies Inc. (NYSE: BHC) had its price target lowered by analysts at Jefferies Financial Group Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BHC provided by MarketBeat
Bausch Health Companies Inc. (NYSE: BHC) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for BHC provided by MarketBeat
News
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets
(*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad i